News
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
HIGHLIGHTS A manuscript describing comprehensive preclinical studies of narmafotinib in models of pancreatic cancer is now available online. The findings provide further evidence of narmafotinib's abi
MCN Adjourns Special Meeting of Shareholders Until August 26, 2026
CHICAGO, July 31, 2026 (GLOBE NEWSWIRE) -- XA Investments, LLC, manager of XAI Madison Equity Premium Income Fund (MCN) (the “Fund”) announced it has adjourned the Fund's Special Meeting of Shareholde
Hang Lung Group Limited (HNLGY) Q2 2026 Earnings Call Transcript
Hang Lung Group Limited (HNLGY) Q2 2026 Earnings Call Transcript
ZOZO, Inc. (SRTTY) Q1 2027 Earnings Call Prepared Remarks Transcript
ZOZO, Inc. (SRTTY) Q1 2027 Earnings Call Prepared Remarks Transcript
New York sues Kalshi, says prediction market is running 'illegal gambling operation'
New York state on Friday sued Kalshi in a Manhattan state court, claiming that the company is illegally operating a gambling platform. Kalshi expressed disappointment with the decision by the state, s
Navigate a Challenging Fixed Income Environment With CLOs
In a tricky fixed income environment marked by high interest rates and ongoing monetary policy uncertainty, collateralized loan obligations (CLOs) are emerging as a strategic alternative. However, inv
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage phar
WELL Health Subsidiary WELLSTAR Closes C$50 Million Financing Transaction Ahead of Planned TSXV Listing
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outc
Kaplan Fox Alerts Investors of a Securities Class Action Against PicS N.V. (PICS) - Deadline is August 4, 2026
New York, New York--(Newsfile Corp. - July 31, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PicS N.V. ("PicS" or the "Company") (NASDAQ: PICS) on be
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by
Kaplan Fox Encourages Badger Meter, Inc. (BMI) Investors with Losses to Contact the Firm Before August 3, 2026
New York, New York--(Newsfile Corp. - July 31, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Badger Meter, Inc. ("Badger Meter" or the "Company") (NY
Engie SA (ENGIY) Q2 2026 Earnings Call Transcript
Engie SA (ENGIY) Q2 2026 Earnings Call Transcript
Fulcrum Therapeutics: Buy It For The Strategic Reset
Fulcrum is trading at a deep discount due to operational distress after the suspension of their main program. But because of their fortress balance sheet, Fulcrum should have the financial strength to
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Prior venetoclax failure - a setting in which published salvage remission rates are approximately 13% and median survival approximately 2. 4 months - shows no adverse impact on blinded composite remis
Fed officials who voted to hike rates say action is needed now against inflation
Fed officials who voted to hike rates say action is needed now against inflation
Forvia SE (FAURY) Q2 2026 Earnings Call Transcript
Forvia SE (FAURY) Q2 2026 Earnings Call Transcript
J-Star Holding Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
TAICHUNG CITY, Taiwan, July 31, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), today announced that it has received a written decision from the Nasdaq He
AbbVie Reports Second-Quarter 2026 Financial Results
Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels
Innate Pharma has an interesting lineup of catalysts with the upcoming IPH4502 data, PACIFIC-9 results, and a potential financing solution for TELLOMAK-3. IPH4502's early responses across several soli
IES Holdings Reports Fiscal 2026 Third Quarter Results and Announces Two-for-One Stock Split
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced financial results for the quarter ended June 30, 2026.
